Diagnostic and Therapeutic Approaches to Hyperinflation and Small Airway Disease in COPD

Universitätsmedizin Mannheim

Status: Completed

Conditions: COPD

Treatments: Drug: mono bronchodilatation; Drug: dual bronchodilatation

Study type: Observational

Funder types: Other

Identifiers

NCT03287921

MBW-hyperinflation

Details and patient eligibility

About

Current guideline-based criteria defining COPD do not meet the challenges set by the complex pathophysiology of the disease. Hyperinflation and affection of the small airways are two components that are not represented in current diagnostic concepts and may relate to early stages of the disease. Moreover, optimal therapeutic interventions in patients with these distinct features remain unclear. The investigators therefore aimed to evaluate novel or not widely used diagnostic approaches for the detection and initiating therapeutic strategies in early stage COPD within the GOLD recommendations.

Enrollment: 26 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• known or first diagnosis of COPD
• lung function testing consistent with hyperinflation or peripheral obstruction
• emphysema in imaging
• symptoms (dyspnea, cough, sputum) and risk factors (>= 10 pack years)
• indication for bronchodilator therapy

Exclusion criteria

• GOLD stages 3 and 4 (spirometric)
• indication for dual bronchodilator therapy, triple therapy or inhaled steroid
• contraindication for cardiopulmonary exercise testing
• unwilling to participate

Trial design

26 participants in 2 patient groups

mono bronchodilatation

Description:

patients with COPD and features of hyperinflation and small airway disease

Treatment:

Drug: dual bronchodilatation

Drug: mono bronchodilatation

dual bronchodilatation

Description:

patients with COPD and features of hyperinflation and small airway disease

Treatment:

Drug: dual bronchodilatation

Drug: mono bronchodilatation